Skip to main content

Rhythm Pharmaceuticals (RYTM) Receives a Buy from Wells Fargo

Tipranks - Tipranks - Thu Jan 8, 5:52AM CST

Wells Fargo analyst Derek Archila maintained a Buy rating on Rhythm Pharmaceuticals yesterday and set a price target of $129.00. The company’s shares closed yesterday at $99.42.

Claim 70% Off TipRanks Premium

Archila covers the Healthcare sector, focusing on stocks such as Incyte, Ascendis Pharma, and Argenx Se. According to TipRanks, Archila has an average return of 16.4% and a 53.97% success rate on recommended stocks.

Rhythm Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $139.62, implying a 40.43% upside from current levels. In a report released on December 22, Bank of America Securities also maintained a Buy rating on the stock with a $140.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Rhythm Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $51.3 million and a GAAP net loss of $52.9 million. In comparison, last year the company earned a revenue of $33.25 million and had a GAAP net loss of $43.64 million

Read More on RYTM:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).